

EDP-305, A Highly Selective and Potent Farnesoid X Receptor Agonist, Favorably Regulates the Expression of Key Fibrogenic Genes *In Vitro* and *In Vivo*

Y. Li¹, J.Y. Shang¹, M.D. Chau¹, M. Roqueta-Rivera¹, K. Garlick¹, P. An², Kahini A. Vaid², G. Wang¹, Y. Popov², Y. S. Or¹, and L. J. Jiang¹

¹Enanta Pharmaceuticals, Inc. Watertown, MA, USA;

²Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA



INTRODUCTION

Fibrosis drives disease progression in people with advanced nonalcoholic steatohepatitis (NASH). EDP-305, a potent Farnesoid X Receptor (FXR) agonist, is currently being developed for the treatment of NASH.

AIM

Herein, we studied the anti-fibrotic activity of EDP-305 *in vitro* and *in vivo*. The effect of EDP-305 on post-transcriptional regulatory mechanism via microRNA29a (miR29a) was also characterized.

METHOD

To investigate the effects of EDP-305 on liver fibrosis *in vitro*, hepatic stellate cells (HSC) were induced with 5ng/ml of transforming growth factor beta (TGFβ) and co-treated with DMSO or EDP-305 for 18 hours. The *in vivo* anti-fibrotic effect of EDP-305 was investigated using mice with methionine/choline-deficient diet (MCD)-induced steatohepatitis and peri-sinusoidal fibrosis. 10 mg/kg of EDP-305 was orally administered to mice 4 weeks after MCD-induced early fibrosis was established and treatment duration was 4 weeks. The expression of essential genes involved in modulating the pathogenic fibrosis response associated with NASH was analyzed by RT-PCR.

RESULTS

EDP-305 significantly ($p < 0.05$) decreased expression of α -smooth muscle actin (α -SMA), collagen type 1 $\alpha 2$ (COL1A2), collagen type 3 $\alpha 1$ (COL3A1), metalloproteinase inhibitor 1 (TIMP1) and metalloproteinase inhibitor 2 (TIMP2) by 68%, 42%, 57%, 80%, 65%, respectively, in the *in vitro* HSC cell culture. Consistent with the *in vitro* observation, these key fibrogenic genes were significantly down-regulated by EDP-305 in mice. Moreover, EDP-305 favorably upregulated miR29a, a crucial player in fibrosis. EDP-305 increased miR29a expression by 89% when compared to the vehicle control, which was associated with 70% reduction of hepatic collagen contents, in mice with MCD-induced fibrosis.

RESULTS (CONTINUED)




Figure 1. Activation of FXR by EDP-305. Chimeric FXR and luciferase reporter constructs were transfected into CHO cells. Luciferase signal was measured after 22 hours of treatment with CDCA (chenodeoxycholic acid), OCA (obeticholic acid), or EDP-305.

Table 1. EDP-305 is >16-fold more potent than OCA and its major metabolites

Compound	FXR (HEK)	TGR5 (CHO)
Obeticholic Acid (OCA)	130 (150)	380 (72)
Glyco-OCA	360 (155)	720 (157)
Tauro-OCA	250 (100)	540 (161)
EDP-305	8 (152)	> 15,000 (NS)

Table 2. EDP-305 Nuclear Receptor Selectivity

Receptor	Relative Selectivity
FXR	1.0
TGR5	> 15,000
VDR	> 15,000
RXR	> 15,000
LXR	> 15,000
PXR	> 15,000
SR	> 15,000
NR1H2	> 15,000
NR1H3	> 15,000
NR1H4	> 15,000
NR1H5	> 15,000
NR1H6	> 15,000
NR1H7	> 15,000
NR1H8	> 15,000
NR1H9	> 15,000
NR1H10	> 15,000
NR1H11	> 15,000
NR1H12	> 15,000
NR1H13	> 15,000
NR1H14	> 15,000
NR1H15	> 15,000
NR1H16	> 15,000
NR1H17	> 15,000
NR1H18	> 15,000
NR1H19	> 15,000
NR1H20	> 15,000
NR1H21	> 15,000
NR1H22	> 15,000
NR1H23	> 15,000
NR1H24	> 15,000
NR1H25	> 15,000
NR1H26	> 15,000
NR1H27	> 15,000
NR1H28	> 15,000
NR1H29	> 15,000
NR1H30	> 15,000
NR1H31	> 15,000
NR1H32	> 15,000
NR1H33	> 15,000
NR1H34	> 15,000
NR1H35	> 15,000
NR1H36	> 15,000
NR1H37	> 15,000
NR1H38	> 15,000
NR1H39	> 15,000
NR1H40	> 15,000
NR1H41	> 15,000
NR1H42	> 15,000
NR1H43	> 15,000
NR1H44	> 15,000
NR1H45	> 15,000
NR1H46	> 15,000
NR1H47	> 15,000
NR1H48	> 15,000
NR1H49	> 15,000
NR1H50	> 15,000
NR1H51	> 15,000
NR1H52	> 15,000
NR1H53	> 15,000
NR1H54	> 15,000
NR1H55	> 15,000
NR1H56	> 15,000
NR1H57	> 15,000
NR1H58	> 15,000
NR1H59	> 15,000
NR1H60	> 15,000
NR1H61	> 15,000
NR1H62	> 15,000
NR1H63	> 15,000
NR1H64	> 15,000
NR1H65	> 15,000
NR1H66	> 15,000
NR1H67	> 15,000
NR1H68	> 15,000
NR1H69	> 15,000
NR1H70	> 15,000
NR1H71	> 15,000
NR1H72	> 15,000
NR1H73	> 15,000
NR1H74	> 15,000
NR1H75	> 15,000
NR1H76	> 15,000
NR1H77	> 15,000
NR1H78	> 15,000
NR1H79	> 15,000
NR1H80	> 15,000
NR1H81	> 15,000
NR1H82	> 15,000
NR1H83	> 15,000
NR1H84	> 15,000
NR1H85	> 15,000
NR1H86	> 15,000
NR1H87	> 15,000
NR1H88	> 15,000
NR1H89	> 15,000
NR1H90	> 15,000
NR1H91	> 15,000
NR1H92	> 15,000
NR1H93	> 15,000
NR1H94	> 15,000
NR1H95	> 15,000
NR1H96	> 15,000
NR1H97	> 15,000
NR1H98	> 15,000
NR1H99	> 15,000
NR1H100	> 15,000

EDP-305 down-regulated inflammatory response genes




Figure 2. Heat map showing the effects of EDP-305 and OCA on expression of genes involved in inflammation. Relative expression of genes, normalized to control, was calculated from delta C_t values.

EDP-305 down-regulated multiple fibrosis-related transcripts in primary human stellate cells





Figure 3. Activation of FXR signaling with EDP-305 significantly inhibited expression of key fibrosis genes *in vitro*. HSCs cells were treated with TGF- β (10 ng/ml) alone or in combination with OCA (0.5 μ M) or EDP-305 (0.5 μ M) for 18 hours ($n=3$ for each treatment). * $p < 0.05$, and ** $p < 0.01$ vs. vehicle with two-way ANOVA.

Scheme of experimental design of MCD feeding-induced steatohepatitis



Effect of treatments on fibrosis (assessed histologically via picrosirius red staining) in MCD-fed mice




Figure 4. Effect of treatments on fibrosis (assessed histologically via picrosirius red staining) in MCD-fed mice. Significant progression of metabolic-type sinusoidal fibrosis ("chicken wire") characteristic of NASH from minimal levels 4 on MCD. "MCD4w start" group is significant (week 4 on MCD, "Placebo" treatment group) in placebo-treated MCD-fed mice. Sinusoidal fibrosis appeared markedly suppressed in MCD-fed mice receiving EDP-305 at 10 mg/kg, but not in OCA-treated group. Representative images of connective tissue staining of livers are shown (200x magnification).

EDP-305 down-regulated multiple fibrosis-related transcripts in MCD-fed mice




Figure 5. Effect of treatments on expression of fibrogenesis gene in MCD-fed mice. *, $p < 0.05$ compared to placebo control group (ANOVA with Dunnett's post-test).

CONCLUSIONS

EDP-305 exhibits potent anti-fibrotic activity *in vitro* and *in vivo*. Moreover, EDP-305 can favorably up-regulate endogenous small non-coding RNA with a critical role in tissue fibrosis. These results warrant further clinical study of EDP-305 for the treatment of NASH.

ACKNOWLEDGEMENTS

We thank Ruichao Shen for preparing all the compounds used in these studies

REFERENCES

Roles of microRNA-29a in the Antifibrotic Effect of Farnesoid X Receptor in Hepatic Stellate Cells. Mol Pharmacol. 2011 Jul; 80(1): 191-200

CONTACT INFORMATION

To request a pdf of this poster, email ljjiang@enanta.com